Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ... oral semaglutide – already approved as Rybelsus for type ...

Biotechnology companies are developing novel obesity medicines to compete with blockbuster weight-loss drugs.

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...